Hollow fiber bioreactor: flexibility across modalities
On demand

Hollow fiber bioreactor: flexibility across modalities

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Hollow fiber bioreactor: flexibility across modalities

The robust flexibility of hollow fiber perfusion technology can cater to many different suspension and adherent cell types, supporting cell therapy commercialization from process development to manufacturing.

Join this webinar for a data deep dive of CD3+ T cell & CD34+ hematopoietic stem cell (HSC) expansion, as well as lentiviral vector production - all from the same platform.

In this webinar you will learn more about:

  • The cell type agnostic flexibility of hollow fiber perfusion technology, without the need for pre-culture expansion
  • T cell expansion data with feed strategies for different media formulations
  • Cord blood-derived CD34 expansion data with minimal residual lymphocyte
  • HEK293 expansion data with lentiviral yields
Mindy Miller
Mindy Miller
Lead Research Scientist at Terumo Blood and Cell Technologies

Mindy Miller currently serves as the lead research scientist within Terumo Blood and Cell Technologies' Cell Therapy Technologies team. She holds a doctorate in Immunology from University of Missouri and conducted post-doctoral studies at University of Missouri, as well as National Jewish Health in Denver, CO.

Mindy’s expertise has focused on the development of immune cells in the context of autoimmunity, allergy and asthma, and pulmonary wound healing. She has authored multiple scientific publications, obtained independent funding, and is the recipient of the Young Investigator Award from the American Association of Immunologists.

Annie  Cunningham
Annie Cunningham
Field Application Scientist, Cell Therapy Technologies at Terumo Blood and Cell Technologies

Annie is currently a Field Application scientist, leading projects on the Quantum Cell Expansion System and FINIA Fill and Finish System. She has spent most of her career in the biotechnology industry, beginning at Seattle Genetics where she was part of the BLA submission and FDA approval of ADCETRIS®, an antibody drug conjugate for CD30+ blood cancer. She then shifted focus into immunotherapy and contributed to the development of a CAR-T program.

Nathan Frank
Nathan Frank
Laboratory Scientist IV at Terumo Blood and Cell Technologies

Nate has more than a decade of experience optimizing parameters for cell and gene therapy production and scale-up. He has specialized expertise in hollow fiber bioreactor process development for a range of cell types aimed at various applications in regenerative medicine and immunotherapy. He is a two-time National Science Foundation fellow and has a passion for teaching and communicating science to a wide range of audiences from established professionals to middle and high school students who are just beginning their scientific journey.